

Haematologica
HAEMATOL/2015/139337
Version 1

Chronic Myeloid Leukemia: Reminiscences and Dreams

Tariq I. Mughal, Jerald P. Radich, Michael W. Deininger, Jane F. Apperley, Timothy P. Hughes, Christine J. Harrison, Carlo Gambacorti-Passerini, Giuseppe Saglio, Jorge Cortes, and George Q. Daley

Disclosures: J.F. Apperley: Scientific advisory board and consultancy: Ariad, Bristol-Myers Squibb, Novartis and Pfizer. J.E. Cortes: Consultancy: Ariad, Bristol-Myers Squibb, Novartis and Pfizer; Research funding: Ariad, Bristol-Myers Squibb, Novartis, Pfizer and Teva. G.Q. Daley: Scientific advisory boards and consultancy: MPM Capital, Johnson & Johnson, True North, Verastem, Epizyme, Ocata Therapeutics, Raze Therapeutics, and Solasia. M.W. Deininger: Scientific advisory boards and consultancy: Bristol-Myers Squibb, Ariad, Novartis and Pfizer; scientific advisory board: Incyte; Research funding: Bristol-Myers Squibb, Novartis, Celgene and Gilead. C. Gambacorti-Passerini: Scientific advisory board: Pfizer; Research funding: Pfizer. C.J. Harrison: No conflicts of interest T.P. Hughes: Scientific advisory boards and consultancy: Bristol-Myers Squibb, Ariad, and Novartis; Research funding: Bristol-Myers Squibb, Ariad and Novartis. T. I. Mughal: Scientific advisory board: Bristol-Myers Squibb; Consultancy: Novartis. J.P. Radich: Consultancy: Novartis, Ariad and Bristol-Myers Squibb; Research support: Novartis. G. Saglio: Scientific advisory boards and consultancy: Bristol-Myers Squibb, Novartis, Ariad and Pfizer.

Contributions: All authors contributed to the writing of the manuscript.